AGY Allergy Therapeutics plc
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, grassmuno, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Allergy Therapeutics (LON: AGY)
›
Allergy Therapeutics (LON: AGY) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 1.225 GBp on 19 November 2026, down 86.2% over 52 weeks.
Its market capitalisation is 77.57M GBP.
Allergy Therapeutics reports return on equity of 142.3%, an operating margin of -63.2% and revenue up 12.3% year over year.
Its debt exceeds its cash by 42.79M GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.